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Abstract
Background: Increased axonal energy demand and mitochondrial
failure have been suggested as possible causes for axonal degener-
ation and disability in multiple sclerosis (MS).
Objective: To test whether ATP depletion precedes clinical, imag-
ing and biomarker evidence for axonal degeneration in MS.
Methods: A longitudinal study including 21 patients with MS. High
Performance Liquid Chromatography (HPLC) was used to quantify
biomarkers of the ATP metabolism (oxypurines and purines) from the
cerebrospinal ﬂuid (CSF) at baseline. The Expanded Disability Status
Scale (EDSS), MRI brain imaging measures for brain atrophy (ven-
tricular and parenchymal fractions) and CSF biomarkers for axonal
damage (phosphorylated and hyperphosphorylated neuroﬁlaments)
were quantiﬁed at baseline and 3-year follow up.
Results: Central ATP depletion (sum of ATP metabolites > 19.7
µmol/L) was followed by more severe progression of disability if com-
pared to normal ATP metabolites (median 1.5 vs 0, p<0.05). Baseline
ATP metabolite levels correlated with change of EDSS in the pooled
cohort (R=0.66, p=0.001) and subgroups (RR patients: R=0.79, p<0.05
and SP/PP patients: R=0.69, p<0.01). There was no relationship be-
tween central ATP metabolites and either biomarker or MRI evidence
for axonal degeneration.
Conclusion: The data suggests that an increased energy demand
in MS causes a quantiﬁable degree of central ATP depletion. We
speculate that the observed clinical disability may be caused by de-
polarisation associated conduction block.Energy penalty in MS 3
1 Introduction
Progression of disability in multiple sclerosis (MS) is hypothesised to be
ultimately linked to axonal loss.1 One of the mechanisms driving axonal
degeneration has suggested to result from virtual hypoxia (reviewed in
reference2). There is some evidence that the increased expression of
sodium channels along demyelinated axons requires an increased amount
of adenosine triphospate (ATP) even at a resting state (reviewed in refer-
ence3). This places an increased energy demand and may result in an
additional energy penalty of neuroelectrical conduction in the damaged
axons. It has been proposed that the exhaustion of ATP stores results in
loss of protective ion–pump function leading to intracellular Ca2+ overload
which then activates a “death cascade”.2,4 Consequently the disintegrating
axons release their cellular content into the adjacent body ﬂuid compart-
ment, the extracellular ﬂuid from were they diffuse into the cerebrospinal
ﬂuid (CSF) (reviewed in reference5). The mentioned Editorial by Waxman3
refers to a landmark paper by Kapoor et al. on axonal vulnerability. Kapoor
et al. demonstrated convincingly how electrically active axons degenerate
in a biochemically hostile environment. Invariably following axonal loss and
neurodegeneration, atrophy of the brain ensues and disability progresses
(reviewed in reference6).
Energy available to cells depends crucially on availability of ATP. In
MS there is accumulating evidence for a mismatch between energy pro-
duction and energy consumption which has been linked genetically and
histologically to mitochondrial dysfunction.7–10 Immunohistochemical and
histochemical studies suggested that particularly complex IV of the res-
piratory chain may be affected in demyelinated axons.8 These authorsEnergy penalty in MS 4
also showed that inhibition of complex IV augmented glutamate mediated
axonal injury,8 a mechanism well recognised from cell biology.11 Mito-
chondrial failure is known to be enhanced by oxidative stress,12 for which
there is convincing post–mortem evidence in MS.7,9 The biochemical con-
sequence of mitochondrial failure is a metabolic imbalance between ATP
consumption and ATP production.13–15 There is a strict correlation be-
tween ATP depletion and concomitant increase of ATP breakdown prod-
ucts (purines and nucleosides).16–19
Therefore exhaustion of the ATP results in an increase of the end prod-
ucts of the metabolic pathway.16–19 The dominant end products of this
pathway are oxypurine (uric acid, hypoxanthine, xanthine) and purine nu-
cleosides (inosine, adenosine, guanosine).16–19 Higher CSF concentra-
tions of total purine nucleosides and total oxypurines in patients with MS
compared to control subjects provide indirect evidence for increased ATP
consumption in MS.20 This ﬁnding rises the question whether increased in
vivo ATP consumption in patients with MS could precede axonal degener-
ation as suggested by the energy insufﬁciency/virtual hypoxia hypothesis.2
In this prospective, longitudinal study we tested if ATP depletion at
baseline would predict the development of axonal degeneration assessed
by three methods: a clinical scale for disability (EDSS), MRI brain atrophy
measures and protein biomarkers for axonal damage.
2 Materials and methods
This study was approved by the IRB and written informed consent was
obtained from all patients.
Two CSF samples (baseline and three year follow up) were available
from 21 patients of a previously reported cohort21 with clinically deﬁniteEnergy penalty in MS 5
MS.22
The Expanded Disability Status Scale score (EDSS)23 was recorded at
baseline and 3–year follow up. Progression of disability was calculated as
∆EDSS = follow up EDSS - baseline–EDSS.
MRI examinations were performed at 1.0 T or 1.5 T at baseline and
followup. In brief, as measures for brain atrophy we used (1) the parenchy-
mal fraction (PF), calculated as the ratio of the whole brain parenchyma to
the intracranial volume and (2) the ventricular fraction (VF) calculated as
the ratio of the ventricular volume to the whole brain parenchyma.24 The
change between baseline and follow up was calculated as ∆PF = follow
up-PF - baseline-PF and ∆VF = follow up-VF - baseline-VF.
Samples of CSF were obtained by routine lumbar puncture. Aliquots of
CSF were centrifuged to remove cellular debris and immediately stored
at -70◦C until assayed. CSF levels of ATP metabolites (uric acid, hy-
poxanthine, xanthine, inosine, adenosine, guanosine) were quantiﬁed by
High Performance Liquid Chromatography (HPLC).20 The sum of the ATP
metabolite levels was considered high if above the range observed in the
control population (mean 13.87, standard deviation 5.83; cut-off > 19.7
µmol/L20). CSF biomarker levels for axonal damage, the phosphorylated
neuroﬁlament heavy chain (NfHSMI35 ) and hyperphosphorylated neuroﬁl-
ament heavy chain (NfHSMI34 ) were quantiﬁed by ELISA25 at baseline and
3–year follow up. The change between baseline and follow up was calcu-
lated as ∆NfH = follow up NfH - baseline–NfH.
Data analysis All statistical analyses and graphs were done using SAS
software (version 9.1.3, SAS Institute, Inc., Cary, North Carolina, USA).
Because of non–Gaussian distribution the median values and the 25–75Energy penalty in MS 6
% interquartile range (IQR) were shown. Independent variables were com-
pared using the non–parametric Kruskall–Wallis test. Analyses of covari-
ance were performed with general linear models. The linear relationship
between continuous variables was evaluated using the Spearman correla-
tion coefﬁcient.
3 Results
The baseline characteristics of the patients are summarised in Table 1.
One–third (7/21) of the MS patients had normal CSF ATP metabolite lev-
els (< 19.7 µmol/L). Two–thirds (14/21) of the MS patients had evidence
for ATP depletion (Table 1). There was no signiﬁcant difference between
the two groups in terms of age, gender distribution, disease duration or
treatment with disease modifying drugs. The median EDSS appeared to
be slightly higher in patients with normal ATP stores, but data distribution
was overlapping and no statistical signiﬁcant difference was found (Ta-
ble 1). This observation was however taken into account for a post–hoc
covariate analysis (see below). Likewise there was no statistical signiﬁcant
difference between MRI atrophy measures (PF, VF) and axonal damage
biomarkers (NfHSMI34 , NfHSMI35 ).
Three years later those patients with evidence for central ATP deple-
tion progressed signiﬁcantly more on the EDSS (median +1.5 points) com-
pared to those with normal central ATP stores (median 0 points, p=0.035,
Table 2). No difference was found for either MRI atrophy measures (∆PV,
∆VF) or axonal damage biomarkers (∆NfHSMI34 , ∆NfHSMI35 ).
Importantly, CSF ATP metabolites correlated signiﬁcantly with the de-
gree of disease progression on the EDSS in the entire cohort(R=0.67,
p=0.001, Figure 1). This correlation was not inﬂuenced by the disease sub-Energy penalty in MS 7
type. In fact the subgroup analysis revealed that signiﬁcance was retained
in RR disease (R=0.79, p<0.05) and SP/PP disease (R=0.69, p<0.01).
In a post–hoc analysis the baseline EDSS was identiﬁed as a relevant
covariate for the statistical analyses on disease progression. Controlling
for this covariate reduced the difference for CSF ATP metabolites below
noise (F=2.54, p=0.12).
No correlations were found between the CSF ATP metabolite levels
and the patients age, disease duration, MRI atrophy measures or axonal
damage biomarkers (data not shown).
4 Discussion
The main ﬁnding of this prospective, longitudinal study was that patients
who suffer from MS and have biomarker evidence for depletion of ATP en-
ergy stores also suffered from signiﬁcantly more disability progression over
the following 3 years compared to patients who had normal ATP energy
stores. This ﬁnding is consistent with the concept that a central energy
penalty may contribute to disability progression in MS.2
An unexpected ﬁnding ﬁnding of this study was that central ATP deple-
tion did not lead to any detectable degree of axonal damage either by MRI
atrophy measures or axonal damage biomarkers. This ﬁnding extends
on a previous observation by Narayana et al. who found that a drop of
NAA could be transient and was not necessarily followed by axonal loss.26
This is interesting because both NAA and ATP are highly concentrated
in mitochondria.27 In fact, NAA synthesis depends on energy from the
ATP metabolism. Decreased NAA peaks were correlated to disability in
a number of studies (reviewed in28). It is therefore conceivable that de-
creased ATP metabolites indicate dysfunction of the mitochondrial energyEnergy penalty in MS 8
metabolism reduced NAA synthesis and disability. This hypothesis would
need to be tested prospectively combining CSF and serial proton mag-
netic resonance spectroscopic imaging in another cohort of MS patients.
It needs to be borne in mind that the present like other clinical in vivo stud-
ies on this hypothesis29 were based on indirect evidence and all ﬁndings
are correlative at best. A statistical signiﬁcant correlation is no proof of
causality. Therefore the hypothesis should also need to be tested in an
experimentally.
How can an ATP energy penalty lead to disability progression with-
out quantiﬁable evidence (MRI and protein biomarkers) for neuro–axonal
loss? Physiologically disability may result from neuroelectrical conduc-
tion block.30 Biochemically it has been shown that synaptic mitochondria
are considerably more vulnerable to an ATP deﬁcit than non–synaptic mi-
tochondria.31,32 It may therefore be possible that the here observed in-
crease of ATP metabolites which we interpret as indirect evidence for cen-
tral ATP depletion may sufﬁce for blocking transmission at the synaptic
level. In addition, conduction may be blocked due to the enhanced en-
ergy demand following increased expression of sodium channels.3 Finally,
conduction may be blocked on a ganglionic level. Rush et al. showed for
voltage gated sodium channels (NAv1.7) that a single mutation (L858H)
can cause hypopolarisation (increased threshold and attenuated repetitive
ﬁring) in one cell population and hyperpolarisation in another cell popu-
lation.33 Crucially, the polarisation pattern depended on the presence of
NAv1.8 channels.33 Experimentally it has been shown that NAv1.8 chan-
nels were upregulated in Purkinje cells of an animal model of MS.34 In
addition, there is human post–mortem evidence for altered expression of
NAv1.2 and NAv1.6 channels in MS plaques.35 It has therefore been pro-Energy penalty in MS 9
posed that MS has features of an acquired channelopathy.36
To summarise, ATP depletion can cause depolarisation and thus con-
duction block on all three levels (synaptic, axonal and ganglionic). This
would explain the relationship between loss of function and indirect CSF
evidence for a central depletion of ATP stores without evidence for sub-
stantial axonal loss on a brain imaging or CSF protein biomarkers level.
One limitation of this argumentation is that conduction block is understood
to be reversible. On the background of our current understanding of con-
duction block it would therefore be difﬁcult to explain how central ATP de-
pletion related depolarisation leads to sustained disability. In fact in a post–
hoc analysis the degree of baseline disability was identiﬁed as an impor-
tant covariate for the statistical results. Therefore any future study aiming
to test the validity of the model would need to compare groups of MS pa-
tients which are matched for their baseline EDSS prospectively. Another
limitation of this study is that the PF/VF measurements were performed
before semi–automated protocols such as SIENA had been validated.37
Future studies could include more detailed and localised atrophy rates.
Taken together, our data suggests that central ATP depletion is as-
sociated with disability progression in MS, possibly due to depolarisation
causing neuroelectrical conduction block. Considering the possibility of
conduction block may be found useful in reﬁning the virtual hypoxia hy-
pothesis.2
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Table 1: Baseline characteristics of MS patients. Pa-
tients were classiﬁed at baseline according to their cen-
tral ATP metabolism. The median (IRQ) is shown, NS
= not signiﬁcant.
MS (all) MS (normal ATP) MS (depleted ATP)
Age (years) 45 (38-51) 49 (40–55) 43 (35–48) NS
Gender (F:M) 12:9 4:3 8:6 NS
Disease duration (years) 13.9 (9.5–19.1) 19.1 (12.6–22.0) 13.45 (7.4–17.0) NS
IFN 8(38%) 3 (43%) 5 (34%) NS
EDSS 4.0 (2.0-6.0) 6.0 (2.5–6.5) 2.25 (1.5–5.5) NS
MRI PF 0.81 (0.79–0.83) 0.80 (0.77–0.83) 0.82 (0.79–0.83) NS
MRI VF 0.03 (0.02–0.04) 0.03 (0.03–0.04) 0.03 (0.02–0.04) NS
CSF NfHSMI34 9 (7–13) 11 (7–19) 9 (7–12) NS
CSF NfHSMI35 78 (17–155) 139 (31–190) 575 (110–123) NS
Number 21 7 14Energy penalty in MS 17
Table 2: Change from baseline to 3–year follow up. The
median (IRQ) is shown.
MS (all) MS (normal ATP) MS (depleted ATP)
∆ EDSS 0.05 (0-1.5) 0 (-0.5–1.0) 1.5 (0–2.0) 0.035
∆ MRI PF 0.015 (-0.005–0.015) 0.02 (-0.03–0.02) 0.01 (0–0.04) NS
∆ MRI VF -0.005 (-0.01–0) -0.01 (-0.01–0) 0 (-0.01– 0) NS
∆ CSF NfHSMI34 19 (-3– 51) 28 (10–95) 2 (-7– 51) NS
∆ CSF NfHSMI35 0 (-78– 87) -11 (-91– 68) 41 (-78– 104) NSEnergy penalty in MS 18
Figure 1: Baseline ATP metabolite levels correlated with the subsequent
progression on the EDSS over the 3–year observation period in the pooled
cohort (Spearman’s R=0.67, p=0.001). Patients with RR disease are in-
dicated by closed circles and patients with SP/PP disease by open trian-
gles. Signiﬁcance of the correlation was retained in the subgroup analyses
(SP/PP disease: R=0.69, p<0.01; RR disease: R=0.79, p<0.05.